SecSonar.com

Kyntra Bio, Inc. (KYNB)

Kyntra Bio, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Kyntra Bio, Inc. (KYNB) is a Medical - Pharmaceuticals company based in US with a market capitalization of $28.1M. Revenue declined 78.3% year-over-year and free cash flow was negative at -$4.8M. This page tracks KYNB's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 225 employees · IPO Nov 14, 2014

Valuation

Valuation & price

$6.82 · as of May 17, 2026 · -45.1% vs 52w high

0.2

P/E ratio

Latest-FY diluted EPS

6.28

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$12.43$8.90$5.37Jul 25Dec 25Jul 26Jul 7, 25$5.37Jul 9, 25$6.19Jul 11, 25$7.15Jul 15, 25$7.32Jul 17, 25$8.07Jul 21, 25$7.56Jul 23, 25$7.55Jul 25, 25$7.45Jul 29, 25$7.18Jul 31, 25$6.92Aug 4, 25$6.93Aug 6, 25$7.11Aug 11, 25$8.37Aug 13, 25$9.88Aug 15, 25$9.49Aug 19, 25$10.56Aug 21, 25$11.09Aug 25, 25$10.63Aug 27, 25$10.48Aug 29, 25$11.83Sep 3, 25$11.96Sep 5, 25$12.10Sep 9, 25$11.48Sep 11, 25$12.43Sep 16, 25$11.51Sep 18, 25$11.38Sep 22, 25$12.23Sep 24, 25$12.38Sep 26, 25$12.31Sep 30, 25$12.25Oct 2, 25$11.93Oct 6, 25$11.31Oct 8, 25$11.40Oct 10, 25$10.55Oct 14, 25$11.07Oct 16, 25$10.77Oct 21, 25$11.15Oct 23, 25$10.71Oct 27, 25$11.12Oct 29, 25$10.91Oct 31, 25$11.12Nov 4, 25$11.00Nov 6, 25$11.00Nov 10, 25$11.00Nov 12, 25$9.13Nov 14, 25$8.69Nov 18, 25$8.60Nov 20, 25$8.30Nov 25, 25$8.56Nov 28, 25$8.80Dec 2, 25$8.08Dec 4, 25$8.25Dec 8, 25$8.36Dec 10, 25$8.82Dec 12, 25$8.38Dec 16, 25$9.51Dec 18, 25$8.32Dec 22, 25$8.56Dec 24, 25$8.59Dec 29, 25$8.78Jan 2, 26$9.16Jan 6, 26$9.02Jan 8, 26$9.50Jan 12, 26$9.07Jan 14, 26$9.50Jan 16, 26$9.14Jan 21, 26$8.74Jan 23, 26$8.74Jan 27, 26$8.43Jan 29, 26$8.01Feb 2, 26$8.16Feb 4, 26$7.86Feb 9, 26$7.83Feb 11, 26$7.80Feb 13, 26$7.45Feb 18, 26$7.79Feb 20, 26$8.32Feb 24, 26$7.28Feb 26, 26$6.97Mar 2, 26$7.05Mar 4, 26$6.92Mar 6, 26$6.84Mar 10, 26$7.13Mar 12, 26$7.02Mar 17, 26$7.37Mar 19, 26$7.30Mar 23, 26$7.06Mar 25, 26$6.79Mar 27, 26$6.59Mar 31, 26$6.78Apr 2, 26$7.01Apr 7, 26$6.92Apr 9, 26$7.19Apr 13, 26$7.08Apr 15, 26$7.12Apr 17, 26$7.32Apr 22, 26$7.19Apr 24, 26$7.14Apr 28, 26$7.05Apr 30, 26$7.27May 4, 26$7.20May 6, 26$7.12May 8, 26$6.95May 12, 26$7.23May 14, 26$7.01May 18, 26$6.83May 20, 26$6.95May 22, 26$6.99May 28, 26$7.02Jun 1, 26$6.90Jun 3, 26$6.81Jun 5, 26$6.71Jun 9, 26$6.69Jun 11, 26$6.76Jun 15, 26$6.87Jun 17, 26$6.91Jun 22, 26$6.88Jun 24, 26$6.94Jun 26, 26$7.24Jul 2, 26$7.63
$5.3752-week range$12.43
Loading valuation history…

Fundamentals

Key fundamentals

$28.1M

Market cap

-78.3%

Revenue growth (YoY)

0.0%

Gross margin

-$4.8M

Free cash flow (USD)

-$89M

Net debt

Net cash position

-96.0%

Share dilution

3/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$179.6MFY 2017$125.7MFY 2018$213.0MFY 2019$256.6MFY 2020$176.3MFY 2021$235.3MFY 2022$140.7MFY 2023$46.8MFY 2024$29.6MFY 2025$6.4M
$179.6M$6.4M

Free cash flow by year

2016 → 2025

FY 2016$5.9MFY 2017$-75.0MFY 2018$-84.2MFY 2019$-84.5MFY 2020$77.6MFY 2021$-112.4MFY 2022$-184.7MFY 2023$-317.5MFY 2024$-138.3MFY 2025$-4.8M
$5.9M-$4.8M

Gross margin by year

2021 → 2025

FY 2021-90.9%FY 202285.6%FY 202391.5%FY 202447.5%FY 20250.0%
-90.9%0.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

2

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 16, 2026Filing
  • 8-K eventFinal Payment ReceivedJun 9, 2026Filing
  • Insider buyInsider Buy $20KWettig Thane · Director, CEO · $19.9KMay 19, 2026Filing
  • Insider buyInsider Buy $20KWettig Thane · Director, CEO · $19.9KMay 18, 2026Filing
  • Quarterly report10-Q FiledMay 12, 2026Filing
  • 8-K eventEarnings ReleaseMay 11, 2026Filing
  • 8-K eventDelisting NoticeApr 9, 2026Filing

Questions

Frequently asked questions

What is Kyntra Bio, Inc.'s market cap?

Kyntra Bio, Inc. (KYNB) has a market capitalization of $28.1M.

What is KYNB's P/E ratio?

KYNB trades at a price-to-earnings ratio of 0.2, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is KYNB's price-to-book (P/B) ratio?

KYNB trades at 6.28 times book value per share.

Are insiders buying KYNB stock?

Yes — SEC Form 4 filings show 2 open-market insider buys and 0 sells at Kyntra Bio, Inc. in the last 90 days.

Same arena

Related companies in Medical - Pharmaceuticals

NEUP

Neuphoria Therapeutics Inc.

$28.6M

SDEV

Stablecoin Development Corp.

$35M

POM

POMDOCTOR Ltd

$12.7M

PETS

PetMed Express, Inc.

$46.7M

YI

111, Inc.

$47.9M

HKPD

Cellyan Biotechnology Co., Ltd

$5.7M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.